Aberdeen firm NovaBiotics is among the finalists in two categories of the Scottish Enterprise (SE) Life Sciences Awards 2014.
It will find out of it has won in categories for innovation and community engagement at a ceremony in Edinburgh on February 6.
NovaBiotics has spent nine years developing a brush-on treatment for a medical condition, nail fungus, affecting more than one in 10 people throughout the world.
The US market alone is expected to be worth about £2billion a year by 2020, meaning potential riches for Craibstone-based NovaBiotics and its Novexatin product.
Other finalists in the Scottish Life Sciences Awards’ innovation category include Aberdeen University spin-out SACCADE Diagnostics and Forres-based AccuNostics.
SACCADE Diagnostics aims to commercialise a novel eye movement test for the diagnosis and clinical management of major psychiatric disorders.
AccuNostics is developing products to improve the lives of the 300million people living with diabetes around the world. North finalists in the commercial collaboration category include partnerships between Landcatch Natural Selection and Edinburgh University’s Roslin Institute, and Open Brolly and NHS Highland.
Salmon farmers Marine Harvest Scotland and Scottish Sea Farms are also in with a chance of winning for their work with Stirling University.
SE life and chemical sciences director Julia Brown said: “The Scottish Life Sciences Awards are highly sought after by the life sciences community.
“The judging panel was again very impressed with the consistently high standards of innovation and business performance in the strong field of nominations.
“This year, we have focused on recognising leadership, activities that support the growth of the sector, product innovation and community engagement.”